Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation

British Journal of Pharmacology

Volumn 171, Issue 1, 2014, Pages 92-106

  Baczko, Istvan ^a   Liknes, David ^b   Yang, Wei ^b   Hamming, Kevin C ^b   Searle, Gavin ^b   Jaeger, Kristian ^b   Husti, Zoltan ^a   Juhasz, Viktor ^a   Klausz, Gergely ^a   Pap, Robert ^a   Saghy, Laszlo ^a   Varro, Andras ^a,c   Dolinsky, Vernon ^d   Wang, Shaohua ^b   Rauniyar, Vivek ^b   Hall, Dennis ^b   Dyck, Jason R B ^e   Light, Peter E ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF ALBERTA   (Canada)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

atrial fibrillation; electrophysiology; ion channels; Kv1.5; pharmacology; resveratrol

Indexed keywords

CALCIUM; COMPOUND 1; PHENOL DERIVATIVE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KV1.5; RESVERATROL; SEA ANEMONE TOXIN; SODIUM CHANNEL NAV1.5; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CHANNEL GATING; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MODEL; DOG; DRUG BLOOD LEVEL; DRUG STRUCTURE; EXCITATION CONTRACTION COUPLING; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTRACELLULAR RECORDING; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; RAT; SODIUM CURRENT; TREATMENT OUTCOME; WHOLE CELL PATCH CLAMP;

ATRIAL FIBRILLATION; ELECTROPHYSIOLOGY; ION CHANNELS; KV1.5; PHARMACOLOGY; RESVERATROL;

ACTION POTENTIALS; ADULT; AGED; ANIMALS; ANIMALS, NEWBORN; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; EXCITATION CONTRACTION COUPLING; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; KV1.5 POTASSIUM CHANNEL; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; NFATC TRANSCRIPTION FACTORS; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHANNEL BLOCKERS; STILBENES; TRANSFECTION;

EID: 84890285069     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12409     Document Type: Article

References (57)

1. Alexander SPH, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
2. Andrews TC, Reimold SC, Berlin JA, Antman EM, (1991). Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 84 (Suppl): III236-III244.
3. Anter E, Jessup M, Callans DJ, (2009). Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 119: 2516-2525.
4. ATP channel-mediated cardioprotection involves posthypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia. FASEB J 19: 980-982.
5. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kuhlkamp V, (1999). Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 44: 121-131.
6. Bouchard RA, Clark RB, Giles WR, (1993). Role of sodium-calcium exchange in activation of contraction in rat ventricle. J Physiol 472: 391-413.
7. Brisdelli F, D'Andrea G, Bozzi A, (2009). Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 10: 530-546.
8. Burashnikov A, Antzelevitch C, (2011). Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther 132: 300-313.
9. Burashnikov A, Antzelevitch C, (2012). Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther 27: 79-89.
10. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C, (2007). Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116: 1449-1457.
11. Caballero R, de la Fuente MG, Gómez R, Barana A, Amorós I, et al. (2010). In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both. J Am Coll Cardiol 55: 2346-2354.
12. Cai BZ, Gong DM, Liu Y, Pan ZW, Xu CQ, Bai YL, et al. (2007). Homocysteine inhibits potassium channels in human atrial myocytes. Clin Exp Pharmacol Physiol 34: 851-855.
13. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. (2012). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33: 2719-2747.
14. Caouette D, Dongmo C, Berube J, Fournier D, Daleau P, (2003). Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line. Naunyn Schmiedebergs Arch Pharmacol 368: 479-486.
15. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, et al. (2001). Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89: E32-E38.
16. Cha YM, Redfield MM, Shen WK, Gersh BJ, (2004). Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109: 2839-2843.
17. Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, et al. (2008). Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem 283: 24194-24201.
18. Chung JH, Manganiello V, Dyck JR, (2012). Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol 22: 546-554.
19. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. (2011). Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365: 2268-2276.
20. Dobrev D, Nattel S, (2010). New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 375: 1212-1223.
21. Dobrev D, Carlsson L, Nattel S, (2012). Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 11: 275-291.
22. Dolinsky VW, Dyck JR, (2011). Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta 1812: 1477-1489.
23. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck JR, (2009). Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119: 1643-1652.
24. Ehrlich JR, Nattel S, (2009). Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? Curr Opin Cardiol 24: 50-55.
25. Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol 52: 105-120.
26. Franz MR, Karasik PL, Li C, Moubarak J, Chavez M, (1997). Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 30: 1785-1792.
27. Gaborit N, Le Bouter S, Szuts V, Varro A, Escande D, Nattel S, et al. (2007). Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol 582 (Pt 2): 675-693.
28. Gaspo R, Bosch RF, Talajic M, Nattel S, (1997). Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 96: 4027-4035.
29. Hart RG, Halperin JL, (2001). Atrial fibrillation and stroke: concepts and controversies. Stroke 32: 803-808.
30. + current by the antifungal drug miconazole. Br J Pharmacol 144: 840-848.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
32. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR, (2003). Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem. 278: 39422-39427.
33. Komukai K, Brette F, Orchard CH, (2002). Electrophysiological response of rat atrial myocytes to acidosis. Am J Physiol Heart Circ Physiol 283: H715-H724.
34. ATP channels from rat heart. J Membr Biol 162: 217-223.
35. Lin CC, Lin JL, Lin CS, Tsai MC, Su MJ, Lai LP, et al. (2004). Activation of the calcineurin-nuclear factor of activated T-cell signal transduction pathway in atrial fibrillation. Chest 126: 1926-1932.
36. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
37. McManus DD, Rienstra M, Benjamin EJ, (2012). An update on the prognosis of patients with atrial fibrillation. Circulation 126: e143-e146.
38. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, et al. (2004). A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 291: 1720-1729.
39. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, et al. (2001). Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104: 174-180.
40. Morillo CA, Klein GJ, Jones DL, Guiraudon CM, (1995). Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 91: 1588-1595.
41. Naccarelli GV, Varker H, Lin J, Schulman KL, (2009). Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104: 1534-1539.
42. Nattel S, Maguy A, Le Bouter S, Yeh YH, (2007). Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 87: 425-456.
43. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B, (2004). Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110: 247-252.
44. Pyrzynska K, Pȩkal A, (2013). Application of free radical diphenylpicrylhydrazyl (DPPH) to estimate the antioxidant capacity of food samples. Anal Methods 5: 4288-4295.
45. Ravens U, Wettwer E, (2011). Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc Res 89: 776-785.
46. Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, et al. (2004). Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer 90: 736-744.
47. Sanguinetti MC, Tristani-Firouzi M, (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
48. +-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A 93: 2208-2212.
49. Taira CA, Opezzo JA, Mayer MA, Hocht C, (2010). Cardiovascular drugs inducing QT prolongation: facts and evidence. Curr Drug Saf 5: 65-72.
50. Tamargo J, Caballero R, Gomez R, Delpon E, (2009). I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs 18: 399-416.
51. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 80: 772-781.
52. Wallace CH, Baczko I, Jones L, Fercho M, Light PE, (2006). Inhibition of cardiac voltage-gated sodium channels by grape polyphenols. Br J Pharmacol 149: 657-665.
53. + current similar to Kv1.5 cloned channel currents. Circ Res 73: 1061-1076.
54. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, et al. (2004). Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94: 110-118.
55. Wolf PA, Abbott RD, Kannel WB, (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983-988.
56. Wu JM, Hsieh TC, (2011). Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 1215: 16-21.
57. Yue L, Feng J, Gaspo R, Li GR, Wang Z, et al. (1997). Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 81: 512-525.